DK2508596T3 - MN/CA IX-specifikke, monoklonale antistoffer genereret fra MN/CA IX-fattige mus, samt anvendelsesfremgangsmåder - Google Patents

MN/CA IX-specifikke, monoklonale antistoffer genereret fra MN/CA IX-fattige mus, samt anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK2508596T3
DK2508596T3 DK12157145.9T DK12157145T DK2508596T3 DK 2508596 T3 DK2508596 T3 DK 2508596T3 DK 12157145 T DK12157145 T DK 12157145T DK 2508596 T3 DK2508596 T3 DK 2508596T3
Authority
DK
Denmark
Prior art keywords
protein
antibodies
domain
cells
seq
Prior art date
Application number
DK12157145.9T
Other languages
English (en)
Inventor
Jaromir Pastorek
Silvia Pastorekova
Miriam Zatovicova
Jan Zavada
Gut Marta Ortova
Zuzanna Zavadova
Original Assignee
Inst Virology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Virology filed Critical Inst Virology
Priority claimed from EP03713562.1A external-priority patent/EP1487972B1/en
Application granted granted Critical
Publication of DK2508596T3 publication Critical patent/DK2508596T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01B—MEASURING LENGTH, THICKNESS OR SIMILAR LINEAR DIMENSIONS; MEASURING ANGLES; MEASURING AREAS; MEASURING IRREGULARITIES OF SURFACES OR CONTOURS
    • G01B3/00—Measuring instruments characterised by the use of mechanical techniques
    • G01B3/10—Measuring tapes
    • G01B3/1084—Tapes combined with arrangements for functions other than measuring lengths
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01B—MEASURING LENGTH, THICKNESS OR SIMILAR LINEAR DIMENSIONS; MEASURING ANGLES; MEASURING AREAS; MEASURING IRREGULARITIES OF SURFACES OR CONTOURS
    • G01B3/00—Measuring instruments characterised by the use of mechanical techniques
    • G01B3/10—Measuring tapes
    • G01B3/1084—Tapes combined with arrangements for functions other than measuring lengths
    • G01B3/1089—Tapes combined with arrangements for functions other than measuring lengths for marking, drawing or cutting
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01B—MEASURING LENGTH, THICKNESS OR SIMILAR LINEAR DIMENSIONS; MEASURING ANGLES; MEASURING AREAS; MEASURING IRREGULARITIES OF SURFACES OR CONTOURS
    • G01B3/00—Measuring instruments characterised by the use of mechanical techniques
    • G01B3/10—Measuring tapes
    • G01B3/1061—Means for displaying or assisting reading of length measurement
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (18)

1. Monoklonalt antistof eller antigenbindende fragment deraf, som specifikt binder til en ikke-immundominant epitop af MN/CA IX protein eller MN/CA IX polypeptid, hvori antistoffet genereres af MN/CA IX-fattige mus, og hvori antistoffet ikke konkurrerer for binding til MN/CA IX med monoklonale antistoffer MN7, M75 eller MN12, under den forudsætning, at antistoffet ikke binder til det proteoglykanlig-nende (PG) domæne af MN/CA IX, og hvori epitopen er valgt blandt epitoperne (a) indenfor kulanhydrase CA) domænet med aminosyresekvensen SEQ ID NO:9, (b) indenfor CA domænet med aminosyresekvensen SEQ ID NO: 101, (c) indenfor CA domænet med aminosyresekvensen SEQ ID NO:67, (d) indenfor CA domænet med aminosyresekvensen SEQ ID NO:69, (e) indenfor transmembrandomænet (TM) med aminosyresekvensen SEQ ID NO:6, og (f) indenfor det intracellulære domæne (IC) med aminosyresekvensen SEQ ID NO:7.
2. Monoklonalt antistof ifølge krav 1, hvori de MN/CA IX-fattige mus har en nulmutation i Car9.
3. Monoklonalt antistof ifølge krav 1, som specifikt binder et MN/CA IX domæne, hvori dette domæne er valgt fra gruppen bestående af kulanhydrase (CA) domænet, transmembran (TM) domænet, og det intracellulære (IC) domæne.
4. Monoklonalt antistof ifølge krav 1, som specifikt binder et MN/CA IX domæne, hvori domænet er kulanhydrasedomænet.
5. Monoklonalt antistof ifølge krav 1, som specifikt binder kulanhydrasedomænet af MN/CA IX protein, som er produceret af hybridomet VU-V/10 deponeret ved BCCM™/LMBPi Ghent, Belgien, under deponeringsnr. LMBP6009 CB.
6. Monoklonalt antistof ifølge krav 5, hvori kulanhydrasedomænet har en amino-syresekvens homolog med SEQ ID NO: 9 eller SEQ ID NO: 101.
7. Monoklonalt antistof ifølge krav 5, som har en epitop indenfor kulanhydrasedomænet, som har aminosyresekvenserne af SEQ ID NO: 7 eller SEQ ID NO: 69 eller en aminosyresekvens, som er homolog med SEQ ID NO: 67 eller SEQ ID NO: 69.
8. Monoklonalt antistof ifølge krav 1, som specifikt binder transmembrandomænet af MN/CA IX protein.
9. Monoklonalt antistof ifølge krav 1, som specifikt binder det intracellulære domæne af MN/CA IX protein.
10. Monoklonalt antistof ifølge krav 1, som er valgt fra gruppen bestående af antigenbindende fragmenter, der omfatter MN/CA IX proteinbindende områder.
11. Monoklonalt antistof ifølge krav 10, hvori fragmenterne er enkeltkædede molekyler omfattende peptidforbundne VH og VL domæner.
12. Hybridomet VU-V/10, som frembringer det monoklonale antistof V/10, og som er blevet deponeret ved BCCM™/LMBP i Ghent, Belgien, under deponeringsnr. LMBP6009 CB.
13. Antistoffet ifølge krav 1, som specifikt binder til opløseligt MN/CA IX polypep-tid.
14. Monoklonalt antistof ifølge krav 11, hvori fragmenterne er blevet dimeriseret.
15. Monoklonalt antistof ifølge krav 8, hvori det transmembrane domæne har en aminosyresekvens, som er homolog med SEQ ID NO: 6, eller har aminosyrese-kvensen SEQ ID NO: 6.
16. Monoklonalt antistof ifølge krav 9, hvori det intracellulære domæne har ami-nosyresekvensen SEQ ID NO: 7 eller en aminosyresekvens, som er homolog med SEQ ID NO: 7.
17. Monoklonalt antistof ifølge krav 9, hvori antistoffet specifikt binder epitopen repræsenteret ved SEQ ID NO: 68.
18. Monoklonalt antistof ifølge krav 9, hvori det intracellulære domæne har ami-nosyresekvensen SEQ ID NO: 7 eller en aminosyresekvens, som er homolog med SEQ ID NO: 7, og hvori antistoffet specifikt binder epitopen repræsenteret ved SEQ ID NO: 68.
DK12157145.9T 2002-02-21 2003-02-21 MN/CA IX-specifikke, monoklonale antistoffer genereret fra MN/CA IX-fattige mus, samt anvendelsesfremgangsmåder DK2508596T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35882402P 2002-02-21 2002-02-21
US38306802P 2002-05-23 2002-05-23
US43149902P 2002-12-05 2002-12-05
EP03713562.1A EP1487972B1 (en) 2002-02-21 2003-02-21 Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use

Publications (1)

Publication Number Publication Date
DK2508596T3 true DK2508596T3 (da) 2015-10-19

Family

ID=27737296

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12157145.9T DK2508596T3 (da) 2002-02-21 2003-02-21 MN/CA IX-specifikke, monoklonale antistoffer genereret fra MN/CA IX-fattige mus, samt anvendelsesfremgangsmåder

Country Status (4)

Country Link
EP (2) EP3031910B1 (da)
CA (1) CA2704273C (da)
DK (1) DK2508596T3 (da)
SI (3) SI2508596T1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Ｐｓｍａ及びｃａ９を標的とするシステム

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
IL63224A (en) 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom
DE3208890A1 (de) 1981-04-22 1982-12-16 Chemische Fabrik Grünau GmbH, 7918 Illertissen Feuerschutz-ummantelung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
CA1341411C (en) 1988-04-16 2002-12-17 Lutz Riechmann Method for producing fv fragments in eukaryotic cells
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6093548A (en) 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
US6069242A (en) 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5955075A (en) 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
KR100282284B1 (ko) 1992-03-11 2001-02-15 유르데 미키 Mn 유전자 및 단백질
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6204370B1 (en) 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297051B1 (en) 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5972353A (en) 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US5989838A (en) 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
WO2000024913A2 (en) 1998-10-23 2000-05-04 Bayer Corporation Mn gene and protein
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US5363394A (en) 1993-08-06 1994-11-08 At&T Bell Laboratories Quantum wire laser
AU2861695A (en) * 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein
US6204887B1 (en) 1998-12-11 2001-03-20 Hitachi America, Ltd. Methods and apparatus for decoding and displaying multiple images using a common processor
DK1487972T3 (da) * 2002-02-21 2015-10-19 Inst Virology MN/CA IX-specifikke, monoklonale antistoffer genereret fra MN/CA IX-fattige mus, samt anvendelsesfremgangsmåder

Also Published As

Publication number Publication date
EP2508596A3 (en) 2013-04-24
EP2508596B1 (en) 2015-08-12
SI3031910T1 (en) 2018-05-31
SI1487972T1 (sl) 2016-03-31
CA2704273A1 (en) 2003-12-04
SI2508596T1 (sl) 2016-01-29
EP3031910B1 (en) 2017-08-16
EP3031910A1 (en) 2016-06-15
EP2508596A2 (en) 2012-10-10
CA2704273C (en) 2016-01-05

Similar Documents

Publication Publication Date Title
DK3031910T3 (da) Mn/ca ix-specifikke monoklonale antistof-fer genereret af mn/ca ix-deficiente mus og anvendelsesmetoder
US6027887A (en) MN gene and protein
US6770438B2 (en) MN gene and protein
US6297041B1 (en) MN gene and protein
US6297051B1 (en) MN gene and protein
WO2003100029A2 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
EP2508596B1 (en) MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
CN101641450A (zh) Mn/ca9剪接变体
AU2008200868B2 (en) Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erb-B2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes
HK1226095A1 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
HK1177474B (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use